CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to ...
Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous ...
Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...
New York, New York-- (Newsfile Corp. - March 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...
The agreement covering the compound petrelintide, announced by Roche on Wednesday, marks renewed efforts to catch up with weight-loss market leaders Novo Nordisk and Eli Lilly .
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...
Shares of Danish obesity-drug maker Novo Nordisk, which provided clinical trial data from its CagriSema product that disappointed investors on Monday, continued their retreat, and are down about 11% ...
Zacks Investment Research on MSN21h
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.
For the final quarter of 2024, the fund returned -5.12%, outpacing the -7.58% result of the benchmark MSCI All Country World ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback